. 2016 Jun 1;7(26):39108–39117. doi: 10.18632/oncotarget.9773

Table 4. Association of GSTO1C* or APOE4 with the MCI classification based either on MMSE or the CERAD composite score (49 MCI patients, 113 controls).

Test	SNP	B(SE)	Odds ratio (95% CI)	Sign.
MMSE	APOE4 (rs429358)	0.437 (0.384)	1.6 (0.7 - 3.3)	0.255
	GSTO1C* (rs4925)	0.397 (0.307)	1.5 (0.8 - 2.7)	0.196
CERAD	APOE4 (rs429358)	1.128 (0.386)	3.1 (1.5 - 6.6)	0.004
	GSTO1C* (rs4925)	0.636 (0.317)	1.9 (1.02 - 3.5)	0.045

Binary logistic regression analyses comparing controls and MCI patients that had been assigned either on the basis of the MMSE score (Methods) or the CERAD composite score (Table 3) were performed on the APOE4 allele or the GSTO1*C allele (rs4925). The genetic markers APOE4 and GSTO1*C are only significantly associated with the CERAD composite score-based classification (lower panel).

Abbreviations: B…Beta value, SE…standard error, CI… confidence interval, Sign. … significance

Table 4. Association of GSTO1*C or APOE4 with the MCI classification based either on MMSE or the CERAD composite score (49 MCI patients, 113 controls).

Table 4. Association of GSTO1C* or APOE4 with the MCI classification based either on MMSE or the CERAD composite score (49 MCI patients, 113 controls).